Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) announced on Dec 12, 2025 that Nasdaq notified the company on Dec 10, 2025 it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders' Equity Rule requiring at least $2,500,000 in stockholders' equity. The notice follows Clearmind's Form 6-K filed Dec 5, 2025. Nasdaq said it will continue to monitor the company's compliance and warned that if Clearmind does not demonstrate compliance at its next periodic report, it may be subject to delisting. The company remains a clinical-stage biotech developing neuroplastogen-derived therapeutics.

Positive

• Regained compliance with Nasdaq Rule 5550(b)(1) on Dec 10, 2025
• Meets the $2,500,000 minimum stockholders' equity threshold

Negative

• Nasdaq will monitor compliance and noncompliance could trigger delisting

Argus Dec 12 session

+3.63% close to close Open Argus

Details

News Market Reaction – CMND

On Dec 12, the day this news came out, CMND closed 3.63% above the previous close.

Data tracked by StockTitan Argus for the Dec 12 session.

Market Context

This announcement confirms that Clearmind regained compliance with Nasdaq’s $2,500,000 minimum stock...

Analysis

This announcement confirms that Clearmind regained compliance with Nasdaq’s $2,500,000 minimum stockholders’ equity requirement, reducing near-term delisting risk tied to equity levels. The move follows multiple registered offerings and a 1-for-40 reverse split aimed at shoring up the balance sheet and listing status. Investors may monitor future periodic reports to see if equity remains above the threshold, alongside ongoing financing activity and clinical trial progress for CMND-100.

Key Figures

Nasdaq equity minimum: $2,500,000 Registered direct offering: $1,297,012.76 Shares in Nov 26 offering: 7,944,868 shares +5 more

Nasdaq equity minimum

$2,500,000

Required stockholders’ equity under Nasdaq Listing Rule 5550(b)(1)

Registered direct offering

$1,297,012.76

Gross proceeds from Nov 26, 2025 offering at $0.12 per share and $0.1199 per pre-funded warrant

Shares in Nov 26 offering

7,944,868 shares

Common shares offered at $0.12 per share

Pre-funded warrants Nov 26

2,865,960 warrants

Pre-funded warrants at $0.1199 with $0.0001 exercise price

Nov 19 equity raise

$2,185,000

Gross proceeds from 10,925,000-share primary offering at $0.20 per share

Shares Nov 19 offering

10,925,000 shares

Common shares sold at $0.20 per share

Reported equity

$1,065,668

Stockholders’ equity reported prior to offerings, below $2.5M Nasdaq minimum

Reverse split ratio

1-for-40

Reverse share split effective December 15, 2025

Historical Context

5 past events · Latest: Dec 10

5 events

1. Dec 10

   Reverse share split

   24h Move

   -6.1%

   1-for-40 reverse split to help regain Nasdaq minimum bid price compliance.

2. Dec 05

   Nasdaq bid notice

   24h Move

   +2.5%

   Nasdaq notified company of noncompliance with $1.00 minimum bid price rule.

3. Dec 02

   Clinical trial dosing

   24h Move

   -9.9%

   First participant dosed in Phase I/IIa CMND-100 trial for alcohol use disorder.

4. Dec 01

   Clinical milestones

   24h Move

   -6.9%

   Positive cohort data and DSMB approval plus new elite site joining trial.

5. Nov 25

   Site enrollment

   24h Move

   -19.4%

   First patient enrollment at new site in Phase I/IIa CMND-100 AUD trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 6-k

1 terms

form 6-k regulatory

"based on the Company’s Form 6-K filed on December 5, 2025, it has regained"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, the Company received a notification letter from Nasdaq stating that, based on the Company’s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”), which requires listed companies to maintain stockholders’ equity of at least $2,500,000.

Nasdaq has informed the Company that it will continue to monitor the Company’s compliance with the Minimum Stockholders’ Equity Rule. If, at the time of the Company’s next periodic report, the Company does not demonstrate compliance with this requirement, the Company may be subject to delisting.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com   

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company’s ability to maintain compliance Nasdaq Listing Rules. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind (CMND) announce on Dec 12, 2025 about Nasdaq compliance?

Clearmind said Nasdaq notified it on Dec 10, 2025 that the company regained compliance with the $2,500,000 minimum stockholders' equity rule.

Which Nasdaq rule did Clearmind (CMND) regain compliance with and what is the threshold?

Clearmind regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders' equity.

When did Nasdaq notify Clearmind (CMND) that it regained compliance?

Nasdaq notified Clearmind on Dec 10, 2025, following the company's Form 6-K filed Dec 5, 2025.

Does Clearmind (CMND) face any ongoing risk after regaining compliance?

Yes. Nasdaq will continue to monitor compliance and the company could be subject to delisting if it is not compliant at its next periodic report.

How does this Nasdaq notice affect Clearmind's stockholders?

The notice indicates regained listing compliance for now but signals continued monitoring and a conditional delisting risk if future reports fail to show compliance.